Search

Your search keyword '"Jost, P.J."' showing total 23 results
Start Over Author "Jost, P.J."
23 results on '"Jost, P.J."'

1. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers

Author

Jahn, A., primary, Rump, A., additional, Widmann, T.J., additional, Heining, C., additional, Horak, P., additional, Hutter, B., additional, Paramasivam, N., additional, Uhrig, S., additional, Gieldon, L., additional, Drukewitz, S., additional, Kübler, A., additional, Bermudez, M., additional, Hackmann, K., additional, Porrmann, J., additional, Wagner, J., additional, Arlt, M., additional, Franke, M., additional, Fischer, J., additional, Kowalzyk, Z., additional, William, D., additional, Weth, V., additional, Oster, S., additional, Fröhlich, M., additional, Hüllein, J., additional, Valle González, C., additional, Kreutzfeldt, S., additional, Mock, A., additional, Heilig, C.E., additional, Lipka, D.B., additional, Möhrmann, L., additional, Hanf, D., additional, Oleś, M., additional, Teleanu, V., additional, Allgäuer, M., additional, Ruhnke, L., additional, Kutz, O., additional, Knurr, A., additional, Laßmann, A., additional, Endris, V., additional, Neumann, O., additional, Penzel, R., additional, Beck, K., additional, Richter, D., additional, Winter, U., additional, Wolf, S., additional, Pfütze, K., additional, Geörg, C., additional, Meißburger, B., additional, Buchhalter, I., additional, Augustin, M., additional, Aulitzky, W.E., additional, Hohenberger, P., additional, Kroiss, M., additional, Schirmacher, P., additional, Schlenk, R.F., additional, Keilholz, U., additional, Klauschen, F., additional, Folprecht, G., additional, Bauer, S., additional, Siveke, J.T., additional, Brandts, C.H., additional, Kindler, T., additional, Boerries, M., additional, Illert, A.L., additional, von Bubnoff, N., additional, Jost, P.J., additional, Metzeler, K.H., additional, Bitzer, M., additional, Schulze-Osthoff, K., additional, von Kalle, C., additional, Brors, B., additional, Stenzinger, A., additional, Weichert, W., additional, Hübschmann, D., additional, Fröhling, S., additional, Glimm, H., additional, Schröck, E., additional, and Klink, B., additional

Published
2022
Full Text
View/download PDF

3. Influence of perioperative administration, transfusion volume and storage age of red blood cell concentrates on clinical outcomes in non-metastatic renal cell carcinoma patients

Author

Barth, D.A., primary, Sareban, N., additional, Lindner, A.K., additional, Daller, L.A.J., additional, Matzhold, E.M., additional, Hutterer, G.C., additional, Smolle, M.A., additional, Riedl, J.M., additional, Huemer, M., additional, Mannweiler, S., additional, Jost, P.J., additional, Bauernhofer, T., additional, Ahyai, S., additional, Zigeuner, R., additional, Pichler, R., additional, and Pichler, M., additional

Published
2022
Full Text
View/download PDF

4. EP02.01-008 Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas

Author

Zacharias, M., primary, Konjic, S., additional, Absenger, G., additional, Hochmair, M.J., additional, Fabikan, H., additional, Weinlinger, C., additional, Illini, O., additional, Jost, P.J., additional, Schlintl, V., additional, Wurm, R., additional, Lindenmann, J., additional, Fediuk, M., additional, Brcic, L., additional, and Terbuch, A., additional

Published
2022
Full Text
View/download PDF

14. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial

Author

Rinaldetti, S. Pfirrmann, M. Manz, K. Guilhot, J. Dietz, C. Panagiotidis, P. Spiess, B. Seifarth, W. Fabarius, A. Müller, M. Pagoni, M. Dimou, M. Dengler, J. Waller, C.F. Brümmendorf, T.H. Herbst, R. Burchert, A. Janβen, C. Goebeler, M.E. Jost, P.J. Hanzel, S. Schafhausen, P. Prange-Krex, G. Illmer, T. Janzen, V. Klausmann, M. Eckert, R. Büschel, G. Kiani, A. Hofmann, W.-K. Mahon, F.-X. Saussele, S.

Abstract

Within the EURO-SKI trial, 132 chronic phase CML patients discontinued imatinib treatment. RNA was isolated from peripheral blood in order to analyze the expression of MDR1, ABCG2 and OCT1. ABCG2 was predictive for treatment-free remission in Cox regression analysis. High transcript levels of the ABCG2 efflux transporter (>4.5‰) were associated with a twofold higher risk of relapse. Introduction: Tyrosine kinase inhibitors (TKIs) can safely be discontinued in chronic myeloid leukemia (CML) patients with sustained deep molecular response. ABCG2 (breast cancer resistance protein), OCT1 (organic cation transporter 1), and ABCB1 (multidrug resistance protein 1) gene products are known to play a crucial role in acquired pharmacogenetic TKI resistance. Their influence on treatment-free remission (TFR) has not yet been investigated. Materials and Methods: RNA was isolated on the last day of TKI intake from peripheral blood leukocytes of 132 chronic phase CML patients who discontinued TKI treatment within the European Stop Tyrosine Kinase Inhibitor Study trial. Plasmid standards were designed including subgenic inserts of OCT1, ABCG2, and ABCB1 together with GUSB as reference gene. For expression analyses, quantitative real-time polymerase chain reaction was used. Multiple Cox regression analysis was performed. In addition, gene expression cutoffs for patient risk stratification were investigated. Results: The TFR rate of 132 patients, 12 months after TKI discontinuation, was 54% (95% confidence interval [CI], 46%-62%). ABCG2 expression (‰) was retained as the only significant variable (P =.02; hazard ratio, 1.04; 95% CI, 1.01-1.07) in multiple Cox regression analysis. Only for the ABCG2 efflux transporter, a significant cutoff was found (P =.04). Patients with an ABCG2/GUSB transcript level >4.5‰ (n = 93) showed a 12-month TFR rate of 47% (95% CI, 37%-57%), whereas patients with low ABCG2 expression (≤4.5‰; n = 39) had a 12-month TFR rate of 72% (95% CI, 55%-82%). Conclusion: In this study, we investigated the effect of pharmacogenetics in the context of a CML treatment discontinuation trial. The transcript levels of the efflux transporter ABCG2 predicted TFR after TKI discontinuation. © 2018 The Authors

Published
2018

17. BCL-2 Inhibition by ABT-199 Potently Induces Cell Death in MDS Progenitors Despite High-Risk Mutations in ASXL1, RUNX1, TP53 or EZH2

Author

Jilg, S., primary, Reidel, V., additional, Kauschinger, J., additional, Müller-Thomas, C., additional, Hauch, R., additional, Schauwecker, J., additional, Burkhard, S., additional, Höckendorf, U., additional, Peschel, C., additional, Kern, W., additional, Haferlach, T., additional, Slotta-Huspenina, J., additional, Götze, K.S., additional, and Jost, P.J., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results